use of notoginsenosid r1 for the treatment of endotoxinschock or heart disease

摘要

PCT No. PCT/AT95/00049 Sec. 371 Date Jan. 4, 1996 Sec. 102(e) Date Jan. 4, 1996 PCT Filed Mar. 16, 1995 PCT Pub. No. WO95/24905 PCT Pub. Date Sep. 21, 1995The use of triterpensaponins, like notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for the production of medicaments for stimulating the fibrinolytic activity and blocking the endotoxin effect, especially for the treatment of patients and animals which suffer from endotoxin shock or to limit the endotoxin shock. Corresponding medicaments are also suitable prophylactive and therapeutic treatment of patients of coronary heart disease, peripheral arterial disease for patients who suffer from angina pectoris and for the prevention of such diseases in healthy persons.